ScreenerHero

HURA TuHURA Biosciences, Inc.

NAS · US · Healthcare · Biotechnology · tuhurabio.com
1.980USD+1.54%Mkt Cap: 126.18M $P/E: —

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune ago…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap126.18M USD
Enterprise Value132.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-30.05M USD
Revenue/Share—
Last Price1.980 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees22
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.22
PEG—
EV/EBITDA-4.29
EV/Revenue—
P/S—
P/B6.82
EPS (TTM)-0.55
EPS (Forward)-0.60
52W Range
0.410052% of range3.430
52W High3.430 USD
52W Low0.4100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-143.57%
ROA-109.87%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.63M USD
CapEx (TTM)76.08K USD
FCF Margin—
FCF Yield-14.48%
Net Debt8.18M USD
Net Debt/EBITDA-0.26
Balance Sheet
Debt/Equity0.03
Current Ratio0.18
Quick Ratio0.14
Book Value/Sh0.29 USD
Cash/Share0.02 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:35
Split DateOct 18, 2024
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.040 USD
Upside (mean)+306.1%
Target Range6.200 USD – 10.00 USD
6.200+306.1% to mean10.00
# Analysts5
Ownership
Shares Out.63.73M
Float39.70M
Insiders34.62%
Institutions14.19%
Short Interest
Short Ratio29.8d
Short % Float12.74%
Short % Out.9.85%
Shares Short6.28M
Short (prev mo.)6.32M
Technical
SMA 502.119 (-6.5%)
SMA 2001.860 (+6.4%)
Beta—
S&P 52W Chg16.45%
Avg Vol (30d)219.84K
Avg Vol (10d)256.70K
Technical Indicators
RSI (14)44.2
MACD-0.0515
MACD Signal-0.0406
MACD Hist.-0.0109
BB Upper2.200 USD
BB Middle2.045 USD
BB Lower1.890 USD
BB Width15.14%
ATR (14)0.1214 USD
Vol Ratio (20d)0.61x